Patent №
US 11,842,805
Granted
2023-12-12
Filed 2022
Owner
CARIS MPI, INC.
Lab
—
AI components
2
ml · planning
Assignment
Recorded
Dataset
AIPD
2023_r1 edition
Application
17831274
Comprehensive molecular profiling provides a wealth of data concerning the molecular status of patient samples. Such data can be compared to patient response to treatments to identify biomarker signatures that predict response or non-response to such treatments. This approach has been applied to identify biomarker signatures that correlate with response of cancer patients to platinum-based chemotherapy. Described herein are data structures, data processing, and machine learning models to predict a probability of benefit of a treatment for a disease or disorder of a subject having a particular set of biomarkers, as well as an exemplary application of such a model to precision medicine, e.g., to methods for selecting a treatment based on a molecular profile, e.g., a treatment comprising platinum therapy.
AI classification
Ownership
CARIS MPI, INC.
assignment · 646250146
Assignors
ABRAHAM, JIM, KORN, WOLFGANG MICHAEL, SPETZLER, DAVID
On an employer assignment, the assignors are typically the inventors.